Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adaptimmune Therapeutics PLC (ADAP : NSDQ)

• Company Description    Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. Number of Employees: 506

• Price / Volume Information    Yesterday's Closing Price: $0.28 Daily Weekly Monthly 20 Day Moving Average: 520,034 shares Shares Outstanding: 265.05 (millions) Market Capitalization: $74.48 (millions) Beta: 2.18 52 Week High: $1.48 52 Week Low: $0.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.54% 6.39% 12 Week 16.02% -4.53% Year To Date -47.84% -51.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 JUBILEE AVENUE MILTON PARK - ABINGDON,X0 OX14 4RX GBR ph: 44-12-3543-0000 fax: 44-12-3543-0001 ir@adaptimmune.com http://www.adaptimmune.com

• General Corporate Information    Officers Adrian Rawcliffe - Chief Executive Officer and Director David M. Mott - Chairman of the Board of Director William Bertrand - Chief Operating Officer Gavin Wood - Chief Financial Officer Andrew Allen - Director Peer Information Adaptimmune Therapeutics PLC (CORR.) Adaptimmune Therapeutics PLC (RSPI) Adaptimmune Therapeutics PLC (CGXP) Adaptimmune Therapeutics PLC (BGEN) Adaptimmune Therapeutics PLC (GTBP) Adaptimmune Therapeutics PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00653A107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 265.05 Most Recent Split Date: (:1) Beta: 2.18 Market Capitalization: $74.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.41 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 30.77% Sales Growth vs. Year Ago Period: 28.30% vs. Previous Quarter: 126.10% ROE 06/30/25 - - 03/31/25 - -163.73 12/31/24 - -117.84 ROA 06/30/25 - - 03/31/25 - -23.65 12/31/24 - -21.90 Current Ratio 06/30/25 - - 03/31/25 - 2.02 12/31/24 - 2.92 Quick Ratio 06/30/25 - - 03/31/25 - 1.79 12/31/24 - 2.80 Operating Margin 06/30/25 - - 03/31/25 - -34.33 12/31/24 - -35.16 Net Margin 06/30/25 - - 03/31/25 - -38.91 12/31/24 - -39.78 Pre-Tax Margin 06/30/25 - - 03/31/25 - -36.89 12/31/24 - -37.77 Book Value 06/30/25 - - 03/31/25 - -0.15 12/31/24 - 0.05 Inventory Turnover 06/30/25 - - 03/31/25 - 0.18 12/31/24 - 0.03 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 4.24 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 80.92

Powered by Zacks Investment Research ©